Cor H. van der Leest

579 citations

16 papers · 289 indexed · h-index 7

Oncology
- Cancer Immunotherapy and Biomarkers 10
- Pancreatic and Hepatic Oncology Research 3
- CAR-T cell therapy research 2
Immunology
- Immunotherapy and Immune Responses 3
Pulmonary and Respiratory Medicine
- Lung Cancer Treatments and Mutations 10
- Lung Cancer Diagnosis and Treatment 2
- Gastric Cancer Management and Outcomes 2
Biotechnology
Cancer Research
Epidemiology
- Neuroendocrine Tumor Research Advances 3

Co-authors: Joachim G.J.V. Aerts Stijn L.W. Koolen Ron H.J. Mathijssen Astrid A.M. van der Veldt Esther Oomen‐de Hoop Reno Debets Edwin A. Basak Sander Bins
Cited by: Oncology Immunology Pulmonary and Respiratory Medicine
Journals: Journal for ImmunoTherapy of Cancer (3 papers)Annals of Oncology (3 papers)Biomedicine & Pharmacotherapy (2 papers)
Partner nations: Netherlands Switzerland Chile

In The Last Decade

Cor H. van der Leest

13 papers receiving 288 citations

Peers

Countries citing papers authored by Cor H. van der Leest

Since Specialization

Citations

This map shows the geographic impact of Cor H. van der Leest's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cor H. van der Leest with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cor H. van der Leest more than expected).

Fields of papers citing papers by Cor H. van der Leest

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cor H. van der Leest. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cor H. van der Leest. The network helps show where Cor H. van der Leest may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Cor H. van der Leest, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Cor H. van der Leest Line = papers co-authored together Cor H. van der Leest links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work
1	The Toxicity Profile of Pemetrexed in Non-Small Cell Lung Cancer Patients With Moderate Renal Impairment: A Retrospective Cohort Study Clinical Lung Cancer ·Christine Der Van Welle,Rob ter Heine,Jiri Stamberg,J W Rose,山城光雄,Bas Peters,Nienke A. G. Lankheet,Terence L. Smith,Т.В. Родионов,Eric J. F. Franssen,Janice O. Bennett,Cor H. van der Leest,Mohammed Bin Hassan Saeed Al Sufran,R.A. Te Velde,Adrian Peter Wiegman,John W.G. van Putten,Ben E.E.M. van den Borne,Michel M. van den Heuvel,Maarten J. Deenen	2025	0
2	The effectiveness of pembrolizumab maintenance with or without pemetrexed after induction treatment for advanced non-squamous Non–Small-Cell Lung cancer Lung Cancer ·Bas Peters,GnanaSagar Tenali,Doranne L. Hilarius,Stefan Böhringer,J. Zwaveling,Geonwhee 김건휘Kim,Cor H. van der Leest,雨春	2025	0
3	1335P The relationship between nivolumab pharmacokinetics and cancer cachexia biomarkers in patients with metastatic non-small cell lung cancer (NSCLC) Annals of Oncology ·Michael S. Hofman,Muhammad Ikhsan Zulfatan Runtukahu,Juliette Degens,Galo Wilfrido Tobar Farías,Daphne W. Dumoulin,Annemie Schols,Nur ÜTKÜR GÜLLÜHAN,Christianne Groeneveldt,Wouter R. P. H. van de Worp,Lizza Hendriks,Cor H. van der Leest,Yi Jia,昭山岡,Anne‐Marie C. Dingemans,Ramon Langen,Azlin Saot	2024	1
4	Bronchiolitis after Combination Immunotherapy With Ipilimumab and Nivolumab in a Melanoma Patient Journal of Immunotherapy ·Dominikus W. Cambu,Charles B. Winterble,Hans M. Westgeest,Аубакиров Улан Сауытбекович,Jochem R. van Werven,Cor H. van der Leest	2024	0
5	A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer Targeted Oncology ·Rob ter Heine,Michel M. van den Heuvel,Berber Piet,Maarten J. Deenen,Anthonie J. van der Wekken,Lizza Hendriks,Sander Croes,Robin M.J.M. van Geel,Frank G. A. Jansman,R.C. Boshuizen,Eric J. F. Franssen,Mohammed Bin Hassan Saeed Al Sufran,Daphne W. Dumoulin,Thijs H. Oude Munnink,Egbert F. Smit,Hieronymus J. Derijks,Cor H. van der Leest,Jeroen J. M. A. Hendrikx,Dirk Jan A. R. Moes,J W Rose	2023	8
6	Clinical Outcomes of Patients With Metastatic NSCLC After Discontinuation of Immunotherapy Because of Immune-Related Adverse Effects JTO Clinical and Research Reports ·Lysanne A. Lievense,Peter Heukels,李洪河,Cor H. van der Leest	2022	6
7	The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy Biomedicine & Pharmacotherapy ·Edwin A. Basak,Karlijn de Joode,蔡中川,I.S Kim,Marco W.J. Schreurs,Sjoerd A.A. van den Berg,Esther Oomen‐de Hoop,Cor H. van der Leest,Layal Chaker,Richard A. Feelders,Astrid A.M. van der Veldt,Arjen Joosse,Stijn L.W. Koolen,Joachim G.J.V. Aerts,Ron H.J. Mathijssen,Sander Bins	2022	4
8	Influence of esomeprazole on the bioavailability of afatinib: A pharmacokinetic cross-over study in patients with non-small cell lung cancer Biomedicine & Pharmacotherapy ·G. Veerman,Daan P. Hurkmans,Marthe S. Paats,Esther Oomen‐de Hoop,Cor H. van der Leest,Gamze Kaplan,Joachim G.J.V. Aerts,Gina Malkusz,Anne‐Marie C. Dingemans,Ron H.J. Mathijssen	2022	1
9	Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors Journal for ImmunoTherapy of Cancer ·Daan P. Hurkmans,Nicole Ó Catháin,Karlijn de Joode,A. Scholenberger,Edwin A. Basak,Annemarie Wijkhuijs,Markus Joerger,Reno Debets,Birgit C. P. Koch,Cor H. van der Leest,Marco W.J. Schreurs,Astrid A.M. van der Veldt,Joachim G.J.V. Aerts,Ron H.J. Mathijssen,Stijn L.W. Koolen	2021	15
10	Influence of Cow’s Milk and Esomeprazole on the Absorption of Erlotinib: A Randomized, Crossover Pharmacokinetic Study in Lung Cancer Patients Clinical Pharmacokinetics ·G. Veerman,Koen G. A. M. Hussaarts,Seoyoung Kang,Esther Oomen‐de Hoop,Alex M. Weber,Cor H. van der Leest,Michael Stitgen,Rebecca Nell Woodrick,Huub Belderbos,Mary Kirkness,Marthe S. Paats,Stijn L.W. Koolen,Anne‐Marie C. Dingemans,Teun van Gelder,Roelof W. F. van Leeuwen,Joachim G.J.V. Aerts,Ron H.J. Mathijssen	2020	11
11	Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer Journal for ImmunoTherapy of Cancer ·Daan P. Hurkmans,Edwin A. Basak,José Julián Echeverry,Esther Oomen‐de Hoop,Cor H. van der Leest,Samira El Bouazzaoui,Sander Bins,Stijn L.W. Koolen,Stefan Sleijfer,Astrid A.M. van der Veldt,Reno Debets,Ron H. N. van Schaik,Joachim G.J.V. Aerts,Ron H.J. Mathijssen	2020	51
12	A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients Journal for ImmunoTherapy of Cancer ·Daan P. Hurkmans,Edwin A. Basak,N. Ba-Diop,João Eudes Bezerra Filho,Marco W.J. Schreurs,Annemarie Wijkhuijs,Sander Bins,Esther Oomen‐de Hoop,Reno Debets,Markus Joerger,Arlette E. Odink,Astrid A.M. van der Veldt,Cor H. van der Leest,Joachim G.J.V. Aerts,Ron H.J. Mathijssen,Stijn L.W. Koolen	2019	66
13	Influence of cow’s milk on the absorption and exposure of erlotinib in NSCLC patients Annals of Oncology ·G. Veerman,Koen G. A. M. Hussaarts,Seoyoung Kang,Esther Oomen‐de Hoop,Alex M. Weber,Cor H. van der Leest,Michael Stitgen,Rebecca Nell Woodrick,Marthe S. Paats,Teun van Gelder,Stijn L.W. Koolen,Joachim G.J.V. Aerts,М.И. Цыгулева,Ron H.J. Mathijssen	2019	1
14	A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients Annals of Oncology ·Daan P. Hurkmans,Edwin A. Basak,Emmalee Mangum,João Eudes Bezerra Filho,Marco W.J. Schreurs,Annemarie Wijkhuijs,Sander Bins,Esther Oomen‐de Hoop,Reno Debets,Markus Joerger,Arlette E. Odink,Astrid A.M. van der Veldt,Cor H. van der Leest,Joachim G.J.V. Aerts,Ron H.J. Mathijssen,Stijn L.W. Koolen	2019	2
15	Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients British Journal of Cancer ·Sander Bins,Edwin A. Basak,Samira El Bouazzaoui,Stijn L.W. Koolen,Esther Oomen‐de Hoop,Cor H. van der Leest,Astrid A.M. van der Veldt,Stefan Sleijfer,Reno Debets,Ron H. N. van Schaik,Joachim G.J.V. Aerts,Ron H.J. Mathijssen	2018	52
16	Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human Clinical Cancer Research ·Joachim G.J.V. Aerts,Pauline L. de Goeje,Robin Cornelissen,Margaretha E.H. Kaijen-Lambers,Koen Bezemer,Cor H. van der Leest,Niken M. Mahaweni,André Kunert,Ferry A.L.M. Eskens,Cynthia Waasdorp,Eric Braakman,Bronno van der Holt,Arnold G. Vulto,Rudi W. Hendriks,Joost P. Hegmans,Henk C. Hoogsteden	2017	71

About Cor H. van der Leest

Cor H. van der Leest is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology, having authored 16 papers that have together received 289 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (10 papers), Lung Cancer Treatments and Mutations (10 papers), Pancreatic and Hepatic Oncology Research (3 papers), Neuroendocrine Tumor Research Advances (3 papers), Immunotherapy and Immune Responses (3 papers), CAR-T cell therapy research (2 papers), Lung Cancer Diagnosis and Treatment (2 papers) and Gastric Cancer Management and Outcomes (2 papers). The work is most often cited by research in Oncology (206 citations), Immunology (93 citations) and Pulmonary and Respiratory Medicine (110 citations). Cor H. van der Leest has collaborated with scholars based in Netherlands, Switzerland and Chile. Frequent co-authors include Joachim G.J.V. Aerts, Stijn L.W. Koolen, Ron H.J. Mathijssen, Astrid A.M. van der Veldt, Esther Oomen‐de Hoop, Reno Debets, Edwin A. Basak, Sander Bins, Daan P. Hurkmans and Samira El Bouazzaoui. Their work appears in journals such as Journal for ImmunoTherapy of Cancer, Annals of Oncology, Biomedicine & Pharmacotherapy, Clinical Cancer Research and Clinical Lung Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact